Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi

Journal of the International AIDS Society

Volumn 18, Issue 1, 2015, Pages

  Herce, Michael E ^a,b,c   Kalanga, Noel ^b,c   Wroe, Emily B ^b,c,d   Keck, James W ^b,c,e   Chingoli, Felix ^f   Tengatenga, Listern ^f   Gopal, Satish ^a   Phiri, Atupere ^b,c   Mailosi, Bright ^b,c   Bazile, Junior ^b,c   Beste, Jason A ^b,c,g   Elmore, Shekinah N ^h   Crocker, Jonathan T ^b,i   Rigodon, Jonas ^b,c,j  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Abwenzi Pa Za Umoyo ^*  (Malawi)

^c PARTNERS IN HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MINISTRY OF HEALTH   (Malawi)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j Haiti Assistance Program   (United States)

more..

Author keywords

Antiretroviral therapy; Bleomycin; Community health worker; Kaposi sarcoma; Malawi; Paclitaxel; Psychosocial support.; Vincristine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLEOMYCIN; HEMOGLOBIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; PACLITAXEL; VINCRISTINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; STAVUDINE, LAMIVUDINE, NEVIRAPINE DRUG COMBINATION;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; DISEASE ASSOCIATION; FEMALE; HEALTH AUXILIARY; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALAWI; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECURRENT DISEASE; RURAL AREA; SIDE EFFECT; THROMBOCYTOPENIA; COHORT ANALYSIS; COMPLICATION; HIV INFECTIONS; RETROSPECTIVE STUDY; RURAL POPULATION; SARCOMA, KAPOSI;

ADULT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALAWI; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES; RURAL POPULATION; SARCOMA, KAPOSI; STAVUDINE;

EID: 84931274677     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.1.19929     Document Type: Article

References (53)

1. IARC. Sub-Saharan Africa population fact sheet. Lyon, France: International Agency for Research on Cancer; 2012.
2. Msyamboza KP, Dzamalala C, Mdokwe C, Kamiza S, Lemerani M, Dzowela T, et al. Burden of cancer in Malawi; common types, incidence and trends: national population-based cancer registry. BMC Res Notes. 2012;5:149.
3. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS; 2013.
4. UNAIDS. The gap report. Geneva: UNAIDS; 2014.
5. Maskew M, MacPhail AP, Whitby D, Egger M, Fox MP. Kaposi sarcomaassociated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults. J Acquir Immune Defic Syndr. 2013;63(4):442-8.
6. Malope-Kgokong BI, Macphail P, Mbisa G, Ratshikhopha E, Maskew M, Stein L, et al. Kaposi's Sarcoma Associated-Herpes Virus (KSHV) seroprevalence in pregnant women in South Africa. Infect Agent Cancer. 2010;5:14.
7. Maskew M, Macphail AP, Whitby D, Egger M,Wallis CL, Fox MP. Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa. Infect Agent Cancer. 2011;6:22.
8. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis. 2008;8:111.
9. Klaskala W, Brayfield BP, Kankasa C, Bhat G, West JT, Mitchell CD, et al. Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia. J Med Virol. 2005;75(1):93-100.
10. Olweny CL, Borok M, Gudza I, Clinch J, Cheang M, Kiire CF, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer. 2005;113(4):632-9.
11. Mwanda OW, Fu P, Collea R, Whalen C, Remick SC. Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya. Ann Trop Med Parasitol. 2005;99(1):81-91.
12. Chu KM, Mahlangeni G, Swannet S, Ford NP, Boulle A, Van Cutsem G. AIDSassociated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J Int AIDS Soc. 2010;13:23.
13. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, Weigel R, et al. Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi. Trop Doctor. 2008;38(1):5-7.
14. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS. 1999;13(15):2105-11.
15. Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004;18(12):1737-40.
16. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010;116(16):3969-77.
17. Gompels MM, Hill A, Jenkins P, Peters B, Tomlinson D, Harris JR, et al. Kaposi's sarcoma in HIV infection treated with vincristine and bleomycin. AIDS. 1992;6(10):1175-80.
18. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16(7):2445-51.
19. Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002;20(15):3236-41.
20. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, Di Trolio R, De Placido S, Dezube BJ. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol. 2007;8(2):167-76.
21. Tulpule A, Groopman J, Saville MW, Harrington W, Jr, Friedman-Kien A, Espina BM, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002;95(1):147-54.
22. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995; 346(8966):26-8.
23. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16(2):683-91.
24. Krown SE. Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities. Curr Opin Oncol. 2011;23(5):463-8.
25. Strother RM, Gregory KM, Pastakia SD, Were P, Tenge C, Busakhala N, et al. Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's sarcoma in western Kenya. Oncology. 2010;78(1): 5-11.
26. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012;60(2):150-7.
27. The World Bank Group. World development indicators. Washington, DC: The World Bank Group; 2013.
28. Neno District Executive Committee. Neno district socioeconomic profile: 2013. Neno, Malawi: Government of Malawi, Ministry of Local Government and Rural Development; 2013.
29. Malawi Ministry of Health. Treatment of AIDS: guidelines for the use of antiretroviral therapy in Malawi. 3rd ed. Lilongwe, Malawi: Malawi Ministry of Health; 2008.
30. Malawi Ministry of Health. Malawi guidelines for the clinical management of HIV in children and adults. 2nd ed. Government of Malawi, Ministry of Health; 2014 [cited 2015 March 25]. Available from: https://www.hiv.health.gov.mw/cha-repository/file.php/84/84.pdf
31. Gopal S, Krysiak R, Liomba G. Building a pathology laboratory in Malawi. Lancet Oncol. 2013;14(4):291-2.
32. Krown SE, Metroka C,Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989; 7(9):1201-7.
33. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15(9):3085-92.
34. Admon AJ, Bazile J, Makungwa H, Chingoli MA, Hirschhorn LR, Peckarsky M, et al. Assessing and improving data quality from community health workers: a successful intervention in Neno, Malawi. Public Health Action. 2013;3(1): 56-9.
35. Wolfe BA, Mamlin BW, Biondich PG, Fraser HS, Jazayeri D, Allen C, et al. The OpenMRS system: collaborating toward an open source EMR for developing countries. AMIA Annu Symp Proc. 2006:1146.
36. Division of AIDS. Table for grading the severity of adult and pediatric adverse events, Version 1.0, December, 2004; Clarification August 2009. Bethesda, Maryland: Division of AIDS, National Institutes of Health; 2009. p. 21.
37. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4(6):e5790.
38. Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, Nanvubya A, et al. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One. 2009;4(2):e4401.
39. Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006;367(9521):1495-502.
40. Borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis. 2010;51(3):342-9.
41. Mlombe Y. Management of HIV associated Kaposi's sarcoma in Malawi. Malawi Med J. 2008;20(4):129-32.
42. Sissolak G, Mayaud P. AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health. 2005;10(10):981-92.
43. World Health Organization. Threshold values for intervention costeffectiveness by region. Geneva: WHO; 2005.
44. Tagar E, Sundaram M, Condliffe K, Matatiyo B, Chimbwandira F, Chilima B, et al. Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facilitylevel ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia. PLoS One. 2014;9(11):e108304.
45. Mintzer DM, Real FX, Jovino L, Krown SE. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1985;102(2):200-2.
46. Mwafongo AA, Rosenberg NE, Ng'ambi W, Werner AB, Garneau WM, Gumulira J, et al. Treatment outcomes of AIDS-associated Kaposi's sarcoma under a routine antiretroviral therapy program in Lilongwe, Malawi: bleomycin/vincristine compared to vincristine monotherapy. PLoS One. 2014;9(3): e91020.
47. Hudnall SD, Rady PL, Tyring SK, Fish JC. Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients. J Infect Dis. 1998;178(6):1791-4.
48. Laker-Oketta MO, Wenger M, Semeere A, Castelnuovo B, Kambugu A, Lukande R, et al. Task Shifting and skin punch for the histologic diagnosis of Kaposi's sarcoma in sub-Saharan Africa: a public health solution to a public health problem. Oncology. 2015;89(1):1-6.
49. Amerson E, Buziba N, Wabinga H, Wenger M, Bwana M, Muyindike W, et al. Diagnosing Kaposi's sarcoma (KS) in East Africa: how accurate are clinicians and pathologists? Infect Agents Cancer. 2012;7(Suppl 1):P6.
50. Banda LT, Parkin DM, Dzamalala CP, Liomba NG. Cancer incidence in Blantyre, Malawi 1994-1998. Trop Med Int Health. 2001;6(4):296-304.
51. Mosam A, Hurkchand HP, Cassol E, Page T, Cassol S, Bodasing U, et al. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. Int J STD AIDS. 2008;19(6):400-5.
52. Meditz AL, Borok M, MaWhinney S, Gudza I, Ndemera B, Gwanzura L, et al. Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe. J Acquir Immune Defic Syndr. 2007;44(3):306-8.
53. Nasti G, Serraino D, Ridolfo A, Antinori A, Rizzardini G, Zeroli C, et al. AIDSassociated Kaposi's sarcoma is more aggressive in women: a study of 54 patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(4):337-41.